Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin

Endocrinology

Volumn 149, Issue 9, 2008, Pages 4589-4595

  Schneyer, Alan L ^a,c   Sidis, Yisrael ^a   Gulati, Anisha ^a   Sun, Jie L ^a   Keutmann, Henry ^a   Krasney, Philip A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c Pioneer Valley Life Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; CYTOKINE RECEPTOR ANTAGONIST; FOLLISTATIN; GROWTH AND DIFFERENTIATION FACTOR 11; MYOSTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; BINDING SITE; BIOASSAY; CRYSTAL STRUCTURE; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUSCLE ATROPHY; MUTANT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; WILD TYPE;

ACTIVINS; BINDING, COMPETITIVE; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; FOLLISTATIN; HUMANS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 50449091974     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0259     Document Type: Article

References (29)

1. Welt C, Sidis Y, Keutmann H, Schneyer A 2002 Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) 227:724-752
2. Oh SP, Yeo CY, Lee Y, Schrewe H, Whitman M, Li E 2002 Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev 16:2749-2754
3. Matzuk MM, Kumar TR, Vassilli A, Bickenbach RR, Roop DR, Jaenisch R, Bradley A 1995 Functional analysis of activins during mammalian development. Nature 374:354-356
4. Sulyok S, Wankell M, Alzheimer C, Werner S 2004 Activin: an important regulator of wound repair, fibrosis, and neuroprotection. Mol Cell Endocrinol 225:127-132
5. Shuto T, Sarkar G, Bronk JT, Matsui N, Bolander ME 1997 Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation. J Bone Miner Res 12:403-411
6. Jones KL, Kretser DM, Patella S, Phillips DJ 2004 Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol 225:119-125
7. Demeterco C, Beattie GM, Dib SA, Lopez AD, Hayek A 2000 A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth. J Clin Endocrinol Metab 85:3892-3897
8. Lee SJ 2004 Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61-86
9. McPherron AC, Lawler AM, Lee SJ 1997 Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387:83-90
10. McPherron AC, Lee SJ 2002 Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109:595-601
11. Harmon EB, Apelqvist AA, Smart NG, Gu X, Osborne DH, Kim SK 2004 GDF11 modulates NGN3+ islet progenitor cell number and promotes β-cell differentiation in pancreas development. Development 131:6163-6174
12. Schneyer A, Sidis Y, Xia Y, Saito S, Re EE, Lin HY, Keutmann H 2004 Differential actions of follistatin and follistatin-like 3. Mol Cell Endocrinol 225:25-28
13. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley Jr WF 1994 Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology 135:667-674
14. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL 2001 Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology 142:3426-3434
15. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A 2006 Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147:3586-3597
16. Matzuk MM, Lu N, Vogel HJ, Sellheyer K, Roop DR, Bradley A 1995 Multiple defects and perinatal death in mice deficient in follistatin. Nature 374:360-363
17. Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, Bloch KD, Thomas MK, Schneyer AL 2007 FSTL3 deletion reveals roles for TGF-β family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci USA 104:1348-1353
18. Guo Q, Kumar TR, Woodruff TW, Hadsell LA, DeMayo FJ, Matzuk MM 1998 Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 12:96-106
19. Xia Y, Sidis Y, Schneyer A 2004 Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice. Mol Endocrinol 18:979-994
20. Lee SJ, McPherron AC 2001 Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98:9306-9311
21. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ 2002 Induction of cachexia in mice by systemically administered myostatin. Science 296:1486-1488
22. Jeevanandam M, Horowitz GD, Lowry SF, Brennan MF 1984 Cancer cachexia and protein metabolism. Lancet 1:1423-1426
23. Lynch GS, Schertzer JD, Ryall JG 2007 Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 113:461-487
24. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S 1998 Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 95:14938-14943
25. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS 2005 The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9:535-543
26. Keutmann HT, Schneyer AL, Sidis Y 2004 The role of follistatin domains in follistatin biological action. Mol Endocrinol 18:228-240
27. Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT 2001 Follistatin: essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem 276:17718-17726
28. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K 2008 Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 22:477-487
29. Tsuchida K 2004 Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metab Disord 4:157-166